PMID- 38067296
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231209
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 23
DP  - 2023 Nov 26
TI  - Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated 
      at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year 
      Single-Center Experience.
LID - 10.3390/cancers15235592 [doi]
LID - 5592
AB  - BACKGROUND: This monocentric retrospective study describes the treatment patterns 
      and outcomes of chronic lymphocytic leukemia (CLL) patients. METHODS: Adult CLL 
      patients treated between 1992 and 2022 were included. The time to next treatment 
      (TTNT) was defined as the time from the treatment's start to the start of a 
      subsequent therapy or death. The time to next treatment failure or death (TTNTF) 
      was defined as the time from treatment discontinuation to the discontinuation of 
      a subsequent therapy or death. RESULTS: Of 637 registered patients, 318 (49.9%) 
      received treatment. We evaluated 157 cBTKi-exposed, 34 BCL2i-exposed cBTKi-naive, 
      and 26 double-exposed patients. The five-year TTNT values in the cBTKi-exposed 
      patients were 80% (median NR), 40% (median 40 months), and 21% (median 24 months) 
      months in the first line (1L), second line (2L), and beyond the second line 
      (>2L), respectively (p < 0.0001). The five-year TTNT values in the BCL2i-exposed 
      patients were 83% (median NR), 72% (median NR), 12% (median 28 months) in the 1L, 
      2L, and >2L, respectively (p = 0.185). The median TTNTF was 9 months (range 1-87) 
      after cBTKi and 17 months (range 8-49) after both a cBTKi and BCL2i. CONCLUSIONS: 
      This study suggests that, in CLL patients, the earlier we used targeted 
      therapies, the better was the outcome obtained. Nonetheless, the poor outcomes in 
      the advanced lines of therapy highlight the need for more effective treatments.
FAU - Innocenti, Idanna
AU  - Innocenti I
AD  - Department of Diagnostic Imaging, Radiation Oncology and Hematology, Fondazione 
      Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
FAU - Fresa, Alberto
AU  - Fresa A
AUID- ORCID: 0000-0002-8084-9009
AD  - Department of Diagnostic Imaging, Radiation Oncology and Hematology, Fondazione 
      Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
AD  - Section of Hematology, Department of Radiological and Hematological Sciences, 
      Catholic University of Sacred Heart, 00168 Rome, Italy.
FAU - Tomasso, Annamaria
AU  - Tomasso A
AD  - Section of Hematology, Department of Radiological and Hematological Sciences, 
      Catholic University of Sacred Heart, 00168 Rome, Italy.
FAU - Tarnani, Michela
AU  - Tarnani M
AD  - Hematology Department, Ospedale Belcolle, 01100 Viterbo, Italy.
FAU - De Padua, Laura
AU  - De Padua L
AD  - Hematology Department, Fabrizio Spaziani Hospital, 03100 Frosinone, Italy.
FAU - Benintende, Giulia
AU  - Benintende G
AD  - Department of Medicine 5, Haematology and Oncology, 
      Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU), Universitatsklinikum, 
      91054 Erlangen, Germany.
FAU - Pasquale, Raffaella
AU  - Pasquale R
AUID- ORCID: 0000-0003-2253-8883
AD  - Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), SOC Clinica Ematologia, 
      33100 Udine, Italy.
FAU - Galli, Eugenio
AU  - Galli E
AUID- ORCID: 0000-0002-2839-916X
AD  - Department of Diagnostic Imaging, Radiation Oncology and Hematology, Fondazione 
      Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
AD  - Section of Hematology, Department of Radiological and Hematological Sciences, 
      Catholic University of Sacred Heart, 00168 Rome, Italy.
FAU - Morelli, Francesca
AU  - Morelli F
AUID- ORCID: 0000-0002-5032-9192
AD  - Department of Hematology, Universita degli Studi di Firenze, 50121 Florence, 
      Italy.
FAU - Giannarelli, Diana
AU  - Giannarelli D
AD  - Facility of Epidemiology and Biostatistics, GSTeP, Fondazione Policlinico 
      Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
FAU - Autore, Francesco
AU  - Autore F
AUID- ORCID: 0000-0002-7868-7469
AD  - Department of Diagnostic Imaging, Radiation Oncology and Hematology, Fondazione 
      Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
FAU - Laurenti, Luca
AU  - Laurenti L
AUID- ORCID: 0000-0002-8327-1396
AD  - Department of Diagnostic Imaging, Radiation Oncology and Hematology, Fondazione 
      Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
AD  - Section of Hematology, Department of Radiological and Hematological Sciences, 
      Catholic University of Sacred Heart, 00168 Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20231126
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10705134
OTO - NOTNLM
OT  - chronic lymphocytic leukemia
OT  - personalized medicine
OT  - targeted therapy
COIS- The authors declare no conflict of interest.
EDAT- 2023/12/09 10:43
MHDA- 2023/12/09 10:44
PMCR- 2023/11/26
CRDT- 2023/12/09 01:03
PHST- 2023/10/19 00:00 [received]
PHST- 2023/11/20 00:00 [revised]
PHST- 2023/11/24 00:00 [accepted]
PHST- 2023/12/09 10:44 [medline]
PHST- 2023/12/09 10:43 [pubmed]
PHST- 2023/12/09 01:03 [entrez]
PHST- 2023/11/26 00:00 [pmc-release]
AID - cancers15235592 [pii]
AID - cancers-15-05592 [pii]
AID - 10.3390/cancers15235592 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Nov 26;15(23):5592. doi: 10.3390/cancers15235592.